TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06307795: A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

Sponsor: Avistone Biotechnology Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 63 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,130,976

Unlock Full NCT06307795 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06307795 Rescue Dossier →